vs
Side-by-side financial comparison of Ballard Power Systems Inc. (BLDP) and CHAMPIONS ONCOLOGY, INC. (CSBR). Click either name above to swap in a different company.
Ballard Power Systems Inc. is the larger business by last-quarter revenue ($17.7M vs $15.0M, roughly 1.2× CHAMPIONS ONCOLOGY, INC.). Ballard Power Systems Inc. runs the higher net margin — 994.4% vs 1.8%, a 992.6% gap on every dollar of revenue.
Ballard Power Systems Inc. is a developer and manufacturer of proton exchange membrane (PEM) fuel cell products for markets such as heavy-duty motive, portable power, material handling as well as engineering services. Ballard has designed and shipped over 400 MW of fuel cell products to date.
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
BLDP vs CSBR — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $17.7M | $15.0M |
| Net Profit | $176.5M | $268.0K |
| Gross Margin | — | 51.7% |
| Operating Margin | — | 1.2% |
| Net Margin | 994.4% | 1.8% |
| Revenue YoY | — | 11.5% |
| Net Profit YoY | — | -63.2% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $15.0M | ||
| Q3 25 | $17.7M | $14.0M | ||
| Q2 25 | — | $12.4M | ||
| Q1 25 | — | $17.0M | ||
| Q4 24 | — | $13.5M | ||
| Q3 24 | $-12.3M | $14.1M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $12.0M |
| Q4 25 | — | $268.0K | ||
| Q3 25 | $176.5M | $-436.0K | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $4.5M | ||
| Q4 24 | — | $728.0K | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | — | $-109.0K | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 51.7% | ||
| Q3 25 | — | 42.9% | ||
| Q2 25 | — | 41.1% | ||
| Q1 25 | — | 61.2% | ||
| Q4 24 | — | 44.9% | ||
| Q3 24 | 156.5% | 49.7% | ||
| Q2 24 | — | 48.2% | ||
| Q1 24 | — | 34.7% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | -3.8% | ||
| Q2 25 | — | -16.2% | ||
| Q1 25 | — | 26.4% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 9.5% | ||
| Q2 24 | — | -1.9% | ||
| Q1 24 | — | -21.4% |
| Q4 25 | — | 1.8% | ||
| Q3 25 | 994.4% | -3.1% | ||
| Q2 25 | — | -14.9% | ||
| Q1 25 | — | 26.4% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | — | 9.3% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | -21.1% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.12 | ||
| Q1 25 | — | $0.31 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $0.09 | ||
| Q2 24 | — | $-0.01 | ||
| Q1 24 | — | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $8.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $4.2M |
| Total Assets | — | $30.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $8.5M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | — | $9.8M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $2.9M | ||
| Q2 24 | — | $2.6M | ||
| Q1 24 | — | $4.5M |
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $3.5M | ||
| Q2 25 | — | $3.8M | ||
| Q1 25 | — | $5.5M | ||
| Q4 24 | — | $681.0K | ||
| Q3 24 | — | $-332.0K | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-2.1M |
| Q4 25 | — | $30.2M | ||
| Q3 25 | — | $30.5M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $30.6M | ||
| Q4 24 | — | $25.2M | ||
| Q3 24 | — | $24.9M | ||
| Q2 24 | — | $26.1M | ||
| Q1 24 | — | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.7M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -13.1% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 0.03× | -6.47× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $5.7M | $600.0K | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $490.0K | ||
| Q4 24 | — | $-283.0K | ||
| Q3 24 | $-6.6M | $311.0K | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-919.0K |
| Q4 25 | — | $-2.0M | ||
| Q3 25 | — | $554.0K | ||
| Q2 25 | — | $6.6M | ||
| Q1 25 | — | $448.0K | ||
| Q4 24 | — | $-377.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-1.0M |
| Q4 25 | — | -13.1% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | -2.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -8.4% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | -6.47× | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | -0.39× | ||
| Q3 24 | — | 0.24× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLDP
Segment breakdown not available.
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
